STEPHEN DAVID NIMER
Affiliation: Memorial Sloan-Kettering Cancer Center
- MDS: a stem cell disorder--but what exactly is wrong with the primitive hematopoietic cells in this disease?Stephen D Nimer
Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, New York, NY 10021, USA
Hematology Am Soc Hematol Educ Program . 2008..Recent studies, using modern molecular detection techniques, have identified new recurring molecular lesions in these disorders but have not really unraveled its pathogenesis...
- Effects of the leukemia-associated AML1-ETO protein on hematopoietic stem and progenitor cellsStephen D Nimer
Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Oncogene 23:4249-54. 2004..The direct effects of AML1-ETO on human and murine HSCs, and the potentially cooperating events that may contribute to its leukemogenic properties, are discussed...
- Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5qStephen D Nimer
Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021 6007, USA
J Clin Oncol 24:2576-82. 2006..This review highlights some issues about the classification and treatment of del(5q) MDS...
- Myelodysplastic syndromes clinical practice guidelines in oncologyPeter L Greenberg
Stanford Hospital and Clinics, Stanford, CA, USA
J Natl Compr Canc Netw 4:58-77. 2006
- Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myelomaHani Hassoun
Division of Hematologic Oncology, Department of Medicine, Hematology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 132:155-61. 2006..AD-TD administered with low dose aspirin for deep vein thrombosis prophylaxis was well tolerated and yielded a high response rate with minimal treatment-related morbidity...
- AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansionJames C Mulloy
Division of Experimental Hematology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
Proc Natl Acad Sci U S A 102:4016-21. 2005....
- Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulationJoseph M Scandura
Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Proc Natl Acad Sci U S A 101:15231-6. 2004..Our studies identify a molecular pathway by which TGFbeta mediates its cytostatic effects on human hematopoietic cells and suggests an explanation for the frequent silencing of p57 expression...
- The transcription factor MEF/ELF4 regulates the quiescence of primitive hematopoietic cellsH Daniel Lacorazza
Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Cancer Cell 9:175-87. 2006..Thus, MEF plays an important role in the decision of stem/primitive progenitor cells to divide or remain quiescent by regulating their entry to the cell cycle...
- Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cellsDonal MacGrogan
Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, New York, New York 10021, USA
Genes Chromosomes Cancer 41:203-13. 2004..These data suggest that L3MBTL is not mutated in MDS or MPD. However, given the known dosage effects of PcG proteins in regulating gene expression, reduced or absent L3MBTL expression may be relevant in some cases of myeloid leukemia...
- TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expressionKeiko Asakura
Division of Hematology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
Mol Cancer Res 2:339-47. 2004....
- Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteinsAnja Moldenhauer
Institute for Transfusion Medicine and Immunehaematology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
J Leukoc Biol 76:623-33. 2004..This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins...
- High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-upLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Neuro Oncol 8:183-8. 2006..This treatment strategy affords long-term disease control to a subset of patients with newly diagnosed anaplastic oligodendroglioma without evidence of delayed neurotoxicity or myelodysplasia...
- Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyHagop Kantarjian
Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 106:1794-803. 2006..Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters...
- Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implicationsDavid H Chang
Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
Blood 108:618-21. 2006..Together these data demonstrate that LEN and its analogues enhance CD1d-mediated presentation of glycolipid antigens and support combining these agents with NKT targeted approaches for protection against tumors...
- DNA damage signaling in hematopoietic cells: a role for Mre11 complex repair of topoisomerase lesionsMonica Morales
Molecular Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center and Cornell University Graduate School of Medical Sciences, New York, NY 10021, USA
Cancer Res 68:2186-93. 2008....
- Is it important to decipher the heterogeneity of "normal karyotype AML"?Stephen D Nimer
Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, NY 1275 York Avenue, New York, NY 10021, USA
Best Pract Res Clin Haematol 21:43-52. 2008..Increased understanding of the biological consequences of at least some of these mutations in "normal karyotype AML" is leading to more targeted approaches to develop more effective treatments for this disease...
- Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblingsHugo Castro-Malaspina
The Allogeneic Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Biol Blood Marrow Transplant 14:458-68. 2008....
- Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activityXinyang Zhao
Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Genes Dev 22:640-53. 2008..These arginine methylation sites and the dynamic regulation of corepressor binding are lost in the leukemia-associated RUNX1-ETO fusion protein, which likely contributes to its dominant inhibitory activity...
- Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromesVirginia M Klimek
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Clin Cancer Res 14:826-32. 2008....
- CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapyPing Zhou
Sloan Kettering Institute, Department of Medicine, New York, NY 10021, USA
Blood 111:3403-6. 2008..These data provide a rationale for the novel therapeutic targeting of CD32B using the humanized 2B6 MoAb in patients with systemic AL-amyloidosis...
- HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTRRichard F Schlenk
University of Ulm, Ulm, Germany
Biol Blood Marrow Transplant 14:187-96. 2008..These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT...
- The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2Yan Liu
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 575, New York, NY 10021, USA
Mol Cell Biol 26:3114-23. 2006..The tight regulation of MEF levels during the cell cycle contributes to its effects on regulating cell cycle entry and cell proliferation...
- Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7Benjamin J Thompson
Department of Pathology, New York University School of Medicine, New York, NY 10016, USA
J Exp Med 205:1395-408. 2008....
- Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's diseaseCraig H Moskowitz
Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, PO Box 350, New York, NY 10021, USA
Br J Haematol 124:645-52. 2004..001). While patients with chemosensitive disease have an excellent outcome with HDT and ASCT, novel approaches are needed to cure HD patients who fail front-line and second-line chemotherapy...
- Severe and selective deficiency of interferon-gamma-producing invariant natural killer T cells in patients with myelodysplastic syndromesShin ichiro Fujii
Laboratory of Tumor Immunology and Immunotherapy, The Rockefeller University, New York, NY 10021, USA
Br J Haematol 122:617-22. 2003..This severe and selective deficiency of an important immune regulatory cell may contribute to the pathogenesis of MDS...
- Transcription factor fusions in acute leukemia: variations on a themeJoseph M Scandura
Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Oncogene 21:3422-44. 2002..g., co-repressor molecules or co-activator molecules). It is these shared features that constitute the 'variations on the theme' that underling the aberrant growth and differentiation that is the hallmark of acute leukemia cells...
- The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cellsH Daniel Lacorazza
Laboratory of Molecular Aspects of Hematopoiesis, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Immunity 17:437-49. 2002..Our results uncover a specific role of MEF in the development and function of NK cells and in innate immunity...
- Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphomaPaul A Hamlin
Lymphoma and Hematology Services, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Box 350, 1275 York Ave, New York, NY, 10021
Blood 102:1989-96. 2003..This powerful prognostic instrument should be used to evaluate new treatment approaches and to compare results of different regimens...
- Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contaminationPing Zhou
Department of Medicine, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Blood 102:477-9. 2003..1%) or 0.5 x 10(4) clonotypic cells per kilogram (range, 0-41.2 x 10(4)/kg), and contamination correlated with CD34+ cells collected (r2 = 0.42, P <.01). Melphalan-mobilized SCCs contain minimal clonotypic contamination...
- De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19Juan C Cigudosa
Cytogenetics Unit, Department of Human Genetics, Spanish National Cancer Center, Melchior Fernandez Almagro, 3 28029 Madrid, Spain
Genes Chromosomes Cancer 36:406-12. 2003..1, 20q11.2, and 21q11.2. This is the first molecular cytogenetic description of the karyotype abnormalities present in patients with ERL. It should assist in the identification of genes involved in erythroleukemogenesis...
- The human L(3)MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL (ETV6)Piernicola Boccuni
Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute for Cancer Research, New York, New York 10021, USA
J Biol Chem 278:15412-20. 2003..We speculate that the interaction of TEL with H-L(3)MBT can direct a PcG complex to genes repressed by TEL, stabilizing their repressed state...
- Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cellsJorg Cammenga
Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center MSKCC, New York, NY 10021, USA
Blood 101:2206-14. 2003..Given the known differences in murine and human promoter regulatory sequences, this inducible system allows the identification of transcription factor target genes in a physiologic, human hematopoietic progenitor cell background...
- Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myelomaCyrus V Hedvat
Laboratory of Molecular Aspects of Hematopoiesis, Sloan Kettering Institute, New York, NY, USA
Br J Haematol 122:728-44. 2003..Defining how malignant plasma cell growth is regulated in the bone marrow versus at extramedullary sites will help to delineate the mechanisms underlying the dependence of tumour cell growth on angiogenesis and cell adhesion...
- Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic elementJames C Mulloy
Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Mail Location 7013, Cincinnati, OH 45229, USA
Blood 102:4369-76. 2003....
- Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remissionJulie M Vose
University of Nebraska Medical Center, Omaha 68198 7680, USA
Biol Blood Marrow Transplant 10:116-27. 2004..Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death...
- Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphomaTarun Kewalramani
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Blood 103:3684-8. 2004..25). RICE appears to induce very high CR rates in patients with relapsed and refractory DLBCL; however, further studies are necessary to determine whether this treatment regimen will improve outcomes after ASCT...
- High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendrogliomaLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York 10021, USA
J Neurooncol 65:127-34. 2003....
- Isolation and characterization of runxa and runxb, zebrafish members of the runt family of transcriptional regulatorsCaroline Erter Burns
Children s Hospital Boston, Boston, MA, USA
Exp Hematol 30:1381-9. 2002..The aim of this study was to isolate runt-related genes in a genetically and embryologically exploitable system, the zebrafish, and characterize their function during hematopoietic development...
- The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cellsJames C Mulloy
Laboratory of Molecular Hematopoiesis, Sloan Kettering Institute, New York, NY, USA
Blood 99:15-23. 2002..Thus, AML1-ETO enhances the self-renewal of pluripotent stem cells, the physiological target of many acute myeloid leukemias...
- The emerging role of the myeloid Elf-1 like transcription factor in hematopoiesisH Daniel Lacorazza
Laboratory of Molecular Aspects of Hematopoiesis, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Blood Cells Mol Dis 31:342-50. 2003..MEF interacts with other TFs such as AML1 (Runx1) and with the cyclin A/cdk2 kinase complex. In this review, we discuss the biology of MEF in the context of the other members of this family of transcriptional regulators...
- Myeloid ELF1-like factor is a potent activator of interleukin-8 expression in hematopoietic cellsCyrus V Hedvat
Laboratory of Molecular Aspects of Hematopoiesis, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Biol Chem 279:6395-400. 2004..MEF overexpression is sufficient to induce IL-8 protein expression, and reduction in MEF expression (using RNA interference) results in decreased IL-8 levels. These data demonstrates that MEF is an important regulator of IL-8 expression...
- Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysisLauren E Abrey
Departments of Neurology and Medicine and the Office of Clinical Research, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 21:4151-6. 2003..To assess the safety and efficacy of intensive methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma (PCNSL)...
- Myelodysplastic syndromesStephen D Nimer
Division of Hematologic Oncology and Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Blood 111:4841-51. 2008....
- Chromosome 19 abnormalities are commonly seen in AML, M7Stephen D Nimer
Blood 100:3838; author reply 3838-9. 2002
- Cytogenetic characterization reveals that the SAM-1 erythroid cell line is derived from K-562 cellsSara Alvarez
Blood 100:3435-6. 2002
- Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphomaCyrus V Hedvat
Laboratory of Cancer Genetics, Cell Biology Program, Department of Pathology and Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Hum Pathol 33:968-74. 2002..This extensive expression profile of B-cell NHLs and HL tissues discloses the ability of TMAs to rapidly screen a large series of cases and represents the first report of method validation for this technique in the study of lymphoma...
- PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesisGang Huang
Hematology Oncology Division, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Harvard Medical School, Boston, Massachusetts 02115, USA
Nat Genet 40:51-60. 2008..1 expression rescued or partially rescued each phenotype. Thus, our data demonstrate that PU.1 is a major downstream target gene of AML1...
- Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML)Thomas Kindler
Johannes Gutenberg University Mainz, 3rd Med Department, Mainz, Germany
Blood 105:335-40. 2005..Since FLT3 tyrosine kinase inhibitors (TKIs) such as PKC412 are currently being investigated in clinical trials in AML, extended sequence analysis of FLT3 may be helpful in defining the spectrum of TKI-sensitive FLT3 mutations in AML...
- OLIG2 (BHLHB1), a bHLH transcription factor, contributes to leukemogenesis in concert with LMO1Ying Wei Lin
Genetics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20889 5105, USA
Cancer Res 65:7151-8. 2005..In addition, growth of leukemic cell lines established from OLIG2/LMO1 transgenic mice was suppressed by a gamma-secretase inhibitor, suggesting that Notch1 up-regulation is important for the proliferation of OLIG2-LMO1 leukemic cells...
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Richard M Stone
Dana Farber Cancer Institute, Boston, MA 02115, USA
Blood 105:54-60. 2005..PKC412 is an oral tyrosine kinase inhibitor with clinical activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy...
- Malignant brain tumor repeats: a three-leaved propeller architecture with ligand/peptide binding pocketsWooi Koon Wang
Cellular Biochemistry and Biophysics Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Structure 11:775-89. 2003..Strikingly, phenotypic alterations resulting from point mutations or deletions in the mbt repeats of the related Drosophila SCM protein are clustered in and around the ligand binding pocket...
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson
Department of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
Blood 108:419-25. 2006..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria...
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsDaniel J DeAngelo
Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
Blood 108:3674-81. 2006..Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity...
- Id1 restrains myeloid commitment, maintaining the self-renewal capacity of hematopoietic stem cellsVladimir Jankovic
Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Proc Natl Acad Sci U S A 104:1260-5. 2007..Thus, Id1 appears to regulate the fate of HSCs by acting as a true inhibitor of differentiation...
- L3MBTL1, a histone-methylation-dependent chromatin lockPatrick Trojer
Howard Hughes Medical Institute, University of Medicine and Dentistry of New Jersey, 683 Hoes Lane, Piscataway, NJ 08854, USA
Cell 129:915-28. 2007..Consistently, L3MBTL1 was found to negatively regulate the expression of a subset of genes regulated by E2F, a factor that interacts with Rb...
- Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphomaTarun Kewalramani
Hematology Services, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Br J Haematol 134:202-7. 2006..The outcome of ASCT for patients with chemosensitive relapsed or primary refractory PTCL is similar to that for patients with DLBCL...
- Vitamin D3 inducible Genes Mediating DifferentiationStephen Nimer; Fiscal Year: 2004..The functional requirement of the DRIP coactivator complex in mediating VDR and RAR transactivation, in the context of nuclear receptor-dependent myeloid differentiation, will be determined. ..
- The function of I(3)mbt in hematopoietic cancersStephen Nimer; Fiscal Year: 2007..The PcG family of proteins is being increasingly implicated in carcinogenesis, and these studies will provide insights into the role that l(3)mbt plays in hematologic malignancies. ..
- FUNCTION OF MEF IN HEMATOPOIETIC CELLSStephen Nimer; Fiscal Year: 2007..abstract_text> ..